Bioventus Q2 Revenue Misses, Launches Strategic Review Including Potential Sale
BVS sits 93% above its 52-week low of $5.81.
Summary
Bioventus missed Q2 revenue estimates by $2.4M ($153.2M vs $155.6M consensus) as surgical solutions declined on tough comps and timing shifts. Adjusted EPS rose a penny to $0.22. The company also announced a strategic alternatives review after receiving acquisition interest, a potential sale process that could reshape the company. Full-year guidance was reaffirmed at $600M-$610M in sales and $0.75-$0.79 adjusted EPS, signaling confidence in the back half. The stock closed at $13.42 on Aug 4, well below the $15 median analyst target.
At the time of this announcement, BVS was trading at $11.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.81 to $14.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.